BD faces risks from global economic downturns, inflation, supply chain disruptions, currency fluctuations, and competition. Product liability lawsuits, regulatory actions (including FDA consent decrees and warning letters), and potential environmental liabilities pose significant financial risks. The company's substantial debt and reliance on external financing also present risks. Uncertain tax positions and the potential for impairment of assets add to the financial uncertainty.

Read More

BD anticipates growth through innovation in smart devices, robotics, and AI. Strategic acquisitions, like the Edwards Lifesciences' Critical Care acquisition, aim to expand market share and product offerings. The company's strong cash position and access to capital markets support investments in R&D and acquisitions. Continued focus on operational efficiency and simplification initiatives could enhance profitability.

Read More